NEW YORK, Oct. 27, 2017 /PRNewswire/ -- The Prix Galien USA Committee last night honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 11th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. In recognition of the development and discovery of products that improve the human condition, the Prix Galien Awards selection committee recognized winners in three categories: "Best Pharmaceutical Product," "Best Biotechnology Product," and "Best Medical Technology."
The 2017 Prix Galien USA Award Winners
"Best Pharmaceutical Product": AbbVie & Genentech (a Member of the Roche Group) for Venclexta™, treatment for people diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least one prior treatment
"Best Biotechnology Product": Biogen & Ionis Pharmaceuticals for SPINRAZA®, treatment of spinal muscular atrophy (SMA) in pediatric and adult patients
"Best Medical Technology": INSIGHTEC for Exablate Neuro, the first focused ultrasound device approved by the FDA to treat essential tremor patients with non-invasive MR-guided focused ultrasound thalamotomy
"These products have been developed by remarkable biomedical researchers who have devoted their lives to making a difference," said Bruno Cohen, Chairman of the Galien Foundation. "The Committee is honored to be able to provide a forum to recognize these outstanding achievements among a distinguished group of industry peers."
In addition to the 2017 product innovation awards, this year's Pro Bono Humanum Award was accepted by Jason Carter, chairman of The Carter Center, on behalf of former U.S. President Jimmy Carter, founder. The Galien Awards Committee selected President Carter as this year's recipient stating, "President Carter follows in a long line of recipients who exemplify the desire for excellence in pursuit of the common good, and that has always been the driving premise of new medical research. We welcome President Carter and The Carter Center to our roster of principled health leaders."
About The Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.